Antibiotic resistance patterns and extended-spectrum β-lactamase production among Acinetobacter spp. isolated from an intensive care Unit of a hospital in Kerman, Iran
Open Access
- 1 January 2012
- journal article
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 1 (1) , 1
Abstract
The global increase in multidrug resistance of Acinetobacter spp. has created widespread problems in the treatment of patients in intensive care units (ICUs) of hospitals. To assess the sensitivity of Acinetobacter isolates to antibiotics routinely used in ICUs, we investigated antibiotic resistance patterns and extended-spectrum β-lactamase (ESBL) production among Acinetobacter spp. isolated from the ICU of a university hospital in Kerman, Iran.Keywords
This publication has 23 references indexed in Scilit:
- Ventilator-associated pneumonia in a tertiary care hospital in India: role of multi-drug resistant pathogensThe Journal of Infection in Developing Countries, 2010
- Antimicrobial Susceptibility Patterns and Distribution of blaOXA Genes among Acinetobacter spp. Isolated from Patients at Tehran HospitalsJapanese Journal of Infectious Diseases, 2008
- Acinetobacter baumannii : Emergence of a Successful PathogenClinical Microbiology Reviews, 2008
- Global Challenge of Multidrug-ResistantAcinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2007
- Antibiotic resistance profile & extended spectrum beta-lactamase (ESBL) production in Acinetobacter species.2007
- Extended-Spectrum β-Lactamases: a Clinical UpdateClinical Microbiology Reviews, 2005
- Antimicrobial resistance of Acinetobacter spp. in EuropeClinical Microbiology and Infection, 2004
- Endemic Carbapenem-resistant Pseudomonas aeruginosa with Acquired Metallo-β-lactamase Determinants in European HospitalEmerging Infectious Diseases, 2004
- Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort studyIntensive Care Medicine, 2003
- Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)Journal of Antimicrobial Chemotherapy, 2002